Literature DB >> 18574260

Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Jack Hirsh1, Gordon Guyatt2, Gregory W Albers3, Robert Harrington4, Holger J Schünemann5.   

Abstract

Since publication of the seventh American College of Chest Physicians (ACCP) supplement on antithrombotic and thrombolytic therapy, the results of clinical trials have provided important new information on the management of thromboembolic disorders, and the science of developing recommendations has advanced. In the accompanying supplement, we provide the new and updated recommendations and review several important changes that we have made in our guideline development process. We again made a conscious effort to increase the participation of female authors and contributors from outside North America, the latter reflecting the widespread use and dissemination of these guidelines internationally. The grading system for the recommendations was adopted in 2006 by the ACCP for all its guidelines, is similar to the increasingly widely used Grades of Recommendation, Assessment, Development, and Evaluation approach, and is described in detail in one of the introductory chapters. While most of the evidence on which recommendations are made remains low quality in fields of pediatric thrombosis, thrombosis in pregnancy, and thrombosis in valvular heart disease, rigorous studies in other fields have resulted in new and strong evidence-based recommendations for many indications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18574260     DOI: 10.1378/chest.08-0652

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  52 in total

1.  Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin.

Authors:  Amani Al-Rossaies; Khalid M Alkharfy; Fakhar Al-Ayoubi; Abdulkareem Al-Momen
Journal:  Int J Clin Pharm       Date:  2011-10-16

2.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Susan L Norris; Sam Schulman; Jack Hirsh; Mark H Eckman; Elie A Akl; Mark Crowther; Per Olav Vandvik; John W Eikelboom; Marian S McDonagh; Sandra Zelman Lewis; David D Gutterman; Deborah J Cook; Holger J Schünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Mesenteric vein thrombosis after laproscopic gastric sleeve procedure.

Authors:  Kaushang Gandhi; Parminder Singh; Mala Sharma; Harit Desai; John Nelson; Ashoutosh Kaul
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

4.  Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil.

Authors:  Renato D Lopes; David Garcia; Richard C Becker; Christopher B Granger; L Kristin Newby; John H Alexander; E Marc Jolicoeur; Allison Handler; Karen S Pieper; Antonio C Carvalho; Helio P Guimaraes; Dalton A F Chamone; Antonio C Baruzzi; Fabio S Machado; Ari Timerman; Antonio C Lopes
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 5.  Challenges of STEMI care in India & the real world.

Authors:  H K Chopra
Journal:  Indian Heart J       Date:  2015-03-14

6.  Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil.

Authors:  Renato D Lopes; Richard C Becker; L Kristin Newby; Eric D Peterson; Elaine M Hylek; Christopher B Granger; Mark Crowther; Tracy Wang; Antonio C Carvalho; Otavio Berwanger; Roberto R Giraldez; Gilson Soares Feitosa; Jorge Pinto Ribeiro; Eduardo Darze; Renato A K Kalil; Marianna Andrande; Fabio Villas Boas; Jadelson Andrade; Ana Thereza Rocha; Robert A Harrington; Antonio C Lopes; David A Garcia
Journal:  J Thromb Thrombolysis       Date:  2012-07       Impact factor: 2.300

7.  Are Evidence Standards Different for Genomic- vs. Clinical-Based Precision Medicine? A Quantitative Analysis of Individualized Warfarin Therapy.

Authors:  D S Dhanda; G F Guzauskas; J J Carlson; A Basu; D L Veenstra
Journal:  Clin Pharmacol Ther       Date:  2017-07-10       Impact factor: 6.875

8.  ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association.

Authors:  C Noel Bairey Merz; Mark J Alberts; Gary J Balady; Christie M Ballantyne; Kathy Berra; Henry R Black; Roger S Blumenthal; Michael H Davidson; Sara B Fazio; Keith C Ferdinand; Lawrence J Fine; Vivian Fonseca; Barry A Franklin; Patrick E McBride; George A Mensah; Geno J Merli; Patrick T O'Gara; Paul D Thompson; James A Underberg
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

Review 9.  New options with dabigatran etexilate in anticoagulant therapy.

Authors:  Lars Maegdefessel; Joshua M Spin; Junya Azuma; Philip S Tsao
Journal:  Vasc Health Risk Manag       Date:  2010-05-25

10.  Prophylactic anticoagulation to prevent venous thromboembolism in traumatic intracranial hemorrhage: a decision analysis.

Authors:  Damon C Scales; Jay Riva-Cambrin; Dave Wells; Valerie Athaide; John T Granton; Allan S Detsky
Journal:  Crit Care       Date:  2010-04-20       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.